Know Cancer

forgot password

Phase I/II Study of the Combination of Bendamustine, Rituximab and MK-2206 in the Treatment of Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Phase 1/Phase 2
18 Years
Open (Enrolling)
B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia

Thank you

Trial Information

Phase I/II Study of the Combination of Bendamustine, Rituximab and MK-2206 in the Treatment of Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma


I. To assess the safety and maximum tolerated dose (MTD) of MK-2206 (Akt inhibitor MK2206)
in combination therapy with bendamustine (bendamustine hydrochloride)-rituximab in relapsed
CLL or SLL patients. (Phase I)

II. To assess the rate of complete response (CR) of MK-2206 in combination with
bendamustine-rituximab in relapsed CLL or SLL patients. (Phase II)


I. To assess clinical efficacy of MK-2206 in combination with bendamustine-rituximab as
demonstrated by analysis of overall response rate (CR, CRi, CCR, nPR and PR), duration of
response, and treatment free survival.

II. To assess the toxicity profile of MK-2206 in combination with bendamustine-rituximab.


I. Evaluation of whether the established CLL prognostic factors (CD38, CD49d, IGHV, FISH and
ZAP-70) predict responses to the combination therapy of MK2206, with bendamustine-rituximab.

II. Minimal residual disease will be evaluated after treatment in patients who achieve a
clinical response. MRD status will be explored in relation to both the quality and duration
of response.

III. Evaluation of the effects of the addition of MK-2206 to bendamustine-rituximab on B
cell receptor initiated, PI3K/Akt downstream signal pathways, apoptosis analysis and
leukemic cell activation status, as well as multiple cytokine profiles and key gene
expression analysis with focus on leukemic cells.

IV. Evaluation of MSC-CLL biology including the effects of the addition of MK-2206 to
bendamustine-rituximab on CLL marrow stromal cell (MSC) proliferation, migration and
cytokine production, as well as the adhesion capacity between MSC and leukemic cells.

OUTLINE: This is a multicenter, phase I dose-escalation study of Akt inhibitor MK2206
followed by a phase II study.

Patients receive Akt inhibitor MK2206 orally (PO) on days 1, 8, 15, 22, and 29 of course 1;
bendamustine hydrochloride intravenously (IV) over 30-60 minutes on days 1-2 (days 8-9 of
course 1); and rituximab IV on day 1 (day 8 of course 1). Treatment repeats every 28 days
(35 days for course 1 and 84 days for course 6) for 6 courses in the absence of disease
progression or unacceptable toxicity.

Blood and bone marrow samples are collected at baseline and periodically during study for
correlative studies.

After completion of study treatment, patients are followed up every 3 months for 2 years and
then every 6 or 12 months for 3 years.

Inclusion Criteria:

- Diagnosis of chronic lymphocytic leukemia (CLL) according to the NCI criteria or
small lymphocytic lymphoma (SLL) according to the WHO criteria, including the prior
documentation of:

- Biopsy-proven SLL

- Diagnosis of CLL as evidence by all of the following:

- Peripheral blood B-cell count of > 5 x 10^9/L consisting of small- to
moderate-size lymphocytes

- Immunophenotyping consistent with CLL defined as:

- The predominant population of lymphocytes share both B-cell antigens
[CD19, CD20 (typically dim expression), or CD23] as well as CD5 in the
absence of other pan-T-cell markers (CD3,CD2, etc.)

- Clonality as evidenced by Κ or λ light chain expression (typically dim
immunoglobulin expression) or other genetic method (e.g.,
immunoglobulin heavy chain variable [IGHV]analysis)

- Splenomegaly, hepatomegaly, or lymphadenopathy are not required for
the diagnosis of CLL

- Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by
demonstrating a negative fluorescence in situ hybridization (FISH) analysis for
t (11;14) (IgH/CCND1) on peripheral blood or tissue biopsy, or negative
immunohisto chemical stains for cyclin D1 on involved tissue biopsy

- Demonstrated progression after one or two prior lines of CLL therapy

- Rituximab monotherapy does not count as a prior line of therapy

- Progressive disease with any one of the following characteristics based on standard
criteria for treatment as defined by the NCI-WG 1996

- Symptomatic CLL characterized by any one of the following:

- Weight loss ≥ 10% within the previous 6 months

- Extreme fatigue attributed to CLL

- Fevers > 100.5° F for 2 weeks without evidence of infection

- Drenching night sweats without evidence of infection

- Evidence of progressive bone marrow failure with hemoglobin< 11 g/dL or platelet
count < 100 x 10^9/L

- Massive or rapidly progressive splenomegaly (> 6 cm below left costal margin)

- Massive (> 10 cm) or rapidly progressive lymphadenopathy

- No primary refractory disease defined by progression while receiving or within 6
months of completion of a chemoimmunotherapy regimen, such as fludarabine phosphate,
cyclophosphamide and rituximab or pentostatin, cyclophosphamide and rituximab

- No FISH abnormality of 17P deletions (phase II only)

- Patients with 17Pdeletions are included in Phase I but will be excluded in Phase
II unless enough activity is found in the Phase I

- No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic

- Patients who have a positive Coombs test but no evidence of hemolysis are NOT
excluded from participation

- Life expectancy ≥ 12 months

- ECOG performance status 0, 1, or 2

- ANC ≥ 1,000/mm³

- Platelet count ≥ 30,000/mm³ (without transfusion)

- Hemoglobin ≥ 8 g/dL

- Cytopenias due to bone marrow failure are common in patients with relapsed CLL
requiring treatment, so normal bone marrow function is NOT required

- Total or direct bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless due to
Gilbert disease)

- SGOT (AST) and SGPT (ALT) ≤ 2.5 times ULN

- Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min/1.73m2

- Negative pregnancy test

- Not pregnant or nursing

- No men or women of childbearing potential who are unwilling to employ adequate

- Ability to complete patient diaries and questionnaire(s) by themselves or with

- Willing to return to North Central Cancer Treatment Group (NCCTG) enrolling
institution for follow-up

- Willing to provide blood samples for correlative research purposes

- Willing to provide bone marrow aspirate for correlative research purposes

- Able to swallow whole tablets

- Nasogastric or G tube administration is not allowed

- No co-morbid systemic illnesses or other severe concurrent disease that, in the
judgment of the investigator, would make the patient inappropriate for entry into
this study or interfere significantly with the proper assessment of safety and
toxicity of the prescribed regimens including, but not limited to, any of the

- New York Heart Association Class III or IV heart disease

- Recent myocardial infarction (< 1 month)

- Uncontrolled infection

- Known infection with the human immunodeficiency virus (HIV/AIDS)and/or patients
taking highly active antiretroviral therapy (HAART)

- Infection with known chronic, active hepatitis C

- Positive serology for hepatitis B (HB) defined as a positive test for HBsAg

- In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb
status), a HB DNA test will be performed and, if positive, the subject will
be excluded

- Uncontrolled diabetes defined as HbA1c ≥ 8 or fasting blood glucose ≥ 140mg/dL

- None of the following:

- History of significant ventricular arrhythmia in the last 5 years including
ventricular tachycardia or ventricular fibrillation

- QTc prolongation on baseline ECG (defined as a QTc interval > 450msec for males
and QTc interval > 470 msec for females)

- Ventricular arrhythmia on baseline ECG (ventricular tachycardia or ventricular
fibrillation ⥠3 beats in a row)

- Second or third degree heart block

- No other active primary malignancy that requires treatment or limits survival to < 24

- No medications or substances that are inducers of CYP450 3A4 ≤ 12 days prior to

- No prior treatment with bendamustine

- No prior treatment with any experimental Akt inhibitors

- No more than 1 prior purine nucleoside-based therapy (i.e., fludarabine, pentostatin,
or cladribine)

- No more than 1 prior alkylating agent-based therapy (i.e., cyclophosphamide or

- No more than 2 total prior lines of therapy for CLL

- No concurrent medication known to cause prolonged QTc

- Not receiving any other investigational agent concurrently that would be considered
as a treatment for the primary neoplasm

- No major surgery ≤ 28 days prior to registration

- No radiotherapy ≤ 4 weeks prior to registration

- No concurrent corticosteroids

- Low-doses of steroids (< 10 mg of prednisone or equivalent dose of other
steroid) for treatment of non-hematologic medical conditions allowed

- Prior use of corticosteroids is allowed

- No medications or substances that are strong or moderate inhibitors ofCYP450 3A4 ≤ 7
days prior to registration

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

MTD of Akt Inhibitor MK2206 in combination with bendamustine hydrochloride and rituximab (Phase I)

Outcome Description:

The descriptions and grading scales found in the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized. The number and severity of all adverse events will be tabulated and summarized in this patient population. The grade 3+ adverse events will also be described and summarized in a similar fashion.

Outcome Time Frame:

After course 1

Safety Issue:


Principal Investigator

Wei Ding

Investigator Role:

Principal Investigator

Investigator Affiliation:

North Central Cancer Treatment Group


United States: Food and Drug Administration

Study ID:




Start Date:

September 2011

Completion Date:

Related Keywords:

  • B-cell Chronic Lymphocytic Leukemia
  • Recurrent Small Lymphocytic Lymphoma
  • Refractory Chronic Lymphocytic Leukemia
  • Stage I Chronic Lymphocytic Leukemia
  • Stage II Chronic Lymphocytic Leukemia
  • Stage III Chronic Lymphocytic Leukemia
  • Stage IV Chronic Lymphocytic Leukemia
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Lymphoma



Mayo Clinic Rochester, Minnesota  55905
Mercy Medical Center - Sioux City Sioux City, Iowa  51104
Fairview Ridges Hospital Burnsville, Minnesota  55337
Fairview Southdale Hospital Edina, Minnesota  55435
Hutchinson Area Health Care Hutchinson, Minnesota  55350
Hennepin County Medical Center - Minneapolis Minneapolis, Minnesota  55415
United Hospital St. Paul, Minnesota  55102
Ridgeview Medical Center Waconia, Minnesota  55387
Rapid City Regional Hospital Rapid City, South Dakota  57709
Adena Regional Medical Center Chillicothe, Ohio  54601
Doctors Hospital at Ohio Health Columbus, Ohio  43228
Riverside Methodist Hospital Cancer Care Columbus, Ohio  43214
Grady Memorial Hospital Delaware, Ohio  43015
Fairfield Medical Center Lancaster, Ohio  43130
Licking Memorial Cancer Care Program at Licking Memorial Hospital Newark, Ohio  43055
Mercy Hospital Coon Rapids, Minnesota  55433
Abbott-Northwestern Hospital Minneapolis, Minnesota  55407
Regions Hospital Saint Paul, Minnesota  55101
Saint Francis Regional Medical Center Shakopee, Minnesota  55379
Rice Memorial Hospital Willmar, Minnesota  56201
Grant Medical Center Cancer Care Columbus, Ohio  43215
Knox Community Hospital Mount Vernon, Ohio  43050
Mayo Clinic in Arizona Scottsdale, Arizona  85259-5404
Columbus CCOP Columbus, Ohio  43206
Metro-Minnesota CCOP St. Louis Park, Minnesota  
Lakeview Hospital Stillwater, Minnesota  55082
Saint Luke's Regional Medical Center Sioux City, Iowa  51104
Miller-Dwan Hospital Duluth, Minnesota  55805
Unity Hospital Fridley, Minnesota  55432
Saint John's Hospital - Healtheast Maplewood, Minnesota  55109
Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota  55109
North Memorial Medical Health Center Robbinsdale, Minnesota  55422
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota  55416
Minnesota Oncology and Hematology PA-Woodbury Woodbury, Minnesota  55125
Mount Carmel Health Center West Columbus, Ohio  43222
Marietta Memorial Hospital Marietta, Ohio  45750
Saint Ann's Hospital Westerville, Ohio  43081
Southern Ohio Medical Center Cancer Center Portsmouth, Ohio  45662
North Central Cancer Treatment Group Rochester, Minnesota  55905
Essentia Health Saint Joseph's Medical Center Brainerd, Minnesota  56401
Essentia Health Duluth Clinic CCOP Duluth, Minnesota  55805
Essentia Health Saint Mary's Medical Center Duluth, Minnesota  55805
Springfield Regional Medical Center Springfield, Ohio  45505
Genesis HealthCare System-Good Samaritan Zanesville, Ohio  43701